vs
Eventbrite, Inc.（EB）与Health Catalyst, Inc.（HCAT）财务数据对比。点击上方公司名可切换其他公司
Health Catalyst, Inc.的季度营收约是Eventbrite, Inc.的1.0倍（$74.7M vs $73.5M），Eventbrite, Inc.净利率更高（-11.1% vs -121.9%，领先110.8%），Eventbrite, Inc.同比增速更快（-3.9% vs -6.2%），Health Catalyst, Inc.自由现金流更多（$9.6M vs $-60.9M），过去两年Health Catalyst, Inc.的营收复合增速更高（-0.0% vs -7.7%）
Eventbrite是源自美国的线下活动服务平台，为用户提供活动浏览、创建与推广服务，支持主办方免费在平台发布不限规模、不限数量的各类活动，是全球范围内活跃度较高的活动交易与推广平台。
Catalyst制药公司是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于开发罕见病治疗药物。其开发的阿米夫斯汀磷酸盐商品名为Firdapse，原本已获FDA批准用于成人兰伯特-伊顿肌无力综合征（LEMS）的治疗，2018年11月又获批可用于6岁及以上儿童LEMS患者。
EB vs HCAT — 直观对比
营收规模更大
HCAT
是对方的1.0倍
$73.5M
营收增速更快
EB
高出2.3%
-6.2%
净利率更高
EB
高出110.8%
-121.9%
自由现金流更多
HCAT
多$70.5M
$-60.9M
两年增速更快
HCAT
近两年复合增速
-7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $73.5M | $74.7M |
| 净利润 | $-8.2M | $-91.0M |
| 毛利率 | 68.1% | — |
| 营业利润率 | -12.4% | -115.3% |
| 净利率 | -11.1% | -121.9% |
| 营收同比 | -3.9% | -6.2% |
| 净利润同比 | 2.5% | -340.3% |
| 每股收益（稀释后） | $-0.08 | $-1.29 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBHCAT
| Q4 25 | $73.5M | $74.7M | ||
| Q3 25 | $71.7M | $76.3M | ||
| Q2 25 | $72.8M | $80.7M | ||
| Q1 25 | $73.8M | $79.4M | ||
| Q4 24 | $76.5M | $79.6M | ||
| Q3 24 | $77.8M | $76.4M | ||
| Q2 24 | $84.6M | $75.9M | ||
| Q1 24 | $86.3M | $74.7M |
净利润EBHCAT
| Q4 25 | $-8.2M | $-91.0M | ||
| Q3 25 | $6.4M | $-22.2M | ||
| Q2 25 | $-2.1M | $-41.0M | ||
| Q1 25 | $-6.6M | $-23.7M | ||
| Q4 24 | $-8.4M | $-20.7M | ||
| Q3 24 | $-3.8M | $-14.7M | ||
| Q2 24 | $1.1M | $-13.5M | ||
| Q1 24 | $-4.5M | $-20.6M |
毛利率EBHCAT
| Q4 25 | 68.1% | — | ||
| Q3 25 | 67.9% | 52.6% | ||
| Q2 25 | 67.5% | — | ||
| Q1 25 | 66.9% | — | ||
| Q4 24 | 68.2% | — | ||
| Q3 24 | 68.5% | 47.5% | ||
| Q2 24 | 70.9% | — | ||
| Q1 24 | 71.0% | — |
营业利润率EBHCAT
| Q4 25 | -12.4% | -115.3% | ||
| Q3 25 | -1.3% | -22.9% | ||
| Q2 25 | -8.7% | -46.0% | ||
| Q1 25 | -13.2% | -25.4% | ||
| Q4 24 | -10.2% | -22.0% | ||
| Q3 24 | -11.5% | -17.9% | ||
| Q2 24 | -7.6% | -20.8% | ||
| Q1 24 | -8.8% | -30.5% |
净利率EBHCAT
| Q4 25 | -11.1% | -121.9% | ||
| Q3 25 | 8.9% | -29.1% | ||
| Q2 25 | -2.9% | -50.8% | ||
| Q1 25 | -9.0% | -29.9% | ||
| Q4 24 | -11.0% | -26.0% | ||
| Q3 24 | -4.8% | -19.3% | ||
| Q2 24 | 1.3% | -17.8% | ||
| Q1 24 | -5.2% | -27.6% |
每股收益（稀释后）EBHCAT
| Q4 25 | $-0.08 | $-1.29 | ||
| Q3 25 | $0.06 | $-0.32 | ||
| Q2 25 | $-0.02 | $-0.59 | ||
| Q1 25 | $-0.07 | $-0.35 | ||
| Q4 24 | $-0.09 | $-0.33 | ||
| Q3 24 | $-0.04 | $-0.24 | ||
| Q2 24 | $0.01 | $-0.23 | ||
| Q1 24 | $-0.05 | $-0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $299.9M | $95.7M |
| 总债务越低越好 | $144.4M | $153.3M |
| 股东权益账面价值 | $179.1M | $245.8M |
| 总资产 | $647.2M | $502.6M |
| 负债/权益比越低杠杆越低 | 0.81× | 0.62× |
8季度趋势，按日历期对齐
现金及短期投资EBHCAT
| Q4 25 | $299.9M | $95.7M | ||
| Q3 25 | — | $91.5M | ||
| Q2 25 | — | $97.3M | ||
| Q1 25 | — | $342.0M | ||
| Q4 24 | $441.5M | $392.0M | ||
| Q3 24 | $24.7M | $387.3M | ||
| Q2 24 | $56.7M | $308.3M | ||
| Q1 24 | $113.7M | $327.8M |
总债务EBHCAT
| Q4 25 | $144.4M | $153.3M | ||
| Q3 25 | $174.9M | $153.1M | ||
| Q2 25 | $241.3M | $153.0M | ||
| Q1 25 | $241.0M | $382.9M | ||
| Q4 24 | $240.7M | $382.4M | ||
| Q3 24 | $240.4M | $345.0M | ||
| Q2 24 | $358.7M | — | ||
| Q1 24 | $358.2M | — |
股东权益EBHCAT
| Q4 25 | $179.1M | $245.8M | ||
| Q3 25 | $189.1M | $331.9M | ||
| Q2 25 | $177.2M | $347.5M | ||
| Q1 25 | $173.3M | $376.8M | ||
| Q4 24 | $170.2M | $365.2M | ||
| Q3 24 | $179.8M | $355.0M | ||
| Q2 24 | $176.2M | $357.0M | ||
| Q1 24 | $184.1M | $357.2M |
总资产EBHCAT
| Q4 25 | $647.2M | $502.6M | ||
| Q3 25 | $744.6M | $587.1M | ||
| Q2 25 | $784.1M | $616.2M | ||
| Q1 25 | $812.3M | $891.5M | ||
| Q4 24 | $752.3M | $858.9M | ||
| Q3 24 | $817.4M | $813.0M | ||
| Q2 24 | $894.5M | $691.7M | ||
| Q1 24 | $952.2M | $695.1M |
负债/权益比EBHCAT
| Q4 25 | 0.81× | 0.62× | ||
| Q3 25 | 0.92× | 0.46× | ||
| Q2 25 | 1.36× | 0.44× | ||
| Q1 25 | 1.39× | 1.02× | ||
| Q4 24 | 1.41× | 1.05× | ||
| Q3 24 | 1.34× | 0.97× | ||
| Q2 24 | 2.04× | — | ||
| Q1 24 | 1.95× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-60.8M | $9.9M |
| 自由现金流经营现金流 - 资本支出 | $-60.9M | $9.6M |
| 自由现金流率自由现金流/营收 | -82.8% | 12.9% |
| 资本支出强度资本支出/营收 | 0.0% | 0.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $17.6M | $-697.0K |
8季度趋势，按日历期对齐
经营现金流EBHCAT
| Q4 25 | $-60.8M | $9.9M | ||
| Q3 25 | $36.7M | $-464.0K | ||
| Q2 25 | $-17.5M | $-9.0M | ||
| Q1 25 | $59.4M | $280.0K | ||
| Q4 24 | $-45.3M | $-3.5M | ||
| Q3 24 | $44.6M | $6.2M | ||
| Q2 24 | $-32.3M | $1.6M | ||
| Q1 24 | $68.6M | $10.3M |
自由现金流EBHCAT
| Q4 25 | $-60.9M | $9.6M | ||
| Q3 25 | $36.6M | $-719.0K | ||
| Q2 25 | $-17.5M | $-9.2M | ||
| Q1 25 | $59.4M | $-390.0K | ||
| Q4 24 | $-45.3M | $-3.9M | ||
| Q3 24 | $44.4M | $5.5M | ||
| Q2 24 | $-32.4M | $1.3M | ||
| Q1 24 | $68.2M | $10.1M |
自由现金流率EBHCAT
| Q4 25 | -82.8% | 12.9% | ||
| Q3 25 | 51.1% | -0.9% | ||
| Q2 25 | -24.1% | -11.4% | ||
| Q1 25 | 80.4% | -0.5% | ||
| Q4 24 | -59.2% | -4.9% | ||
| Q3 24 | 57.1% | 7.2% | ||
| Q2 24 | -38.3% | 1.7% | ||
| Q1 24 | 79.1% | 13.5% |
资本支出强度EBHCAT
| Q4 25 | 0.0% | 0.4% | ||
| Q3 25 | 0.0% | 0.3% | ||
| Q2 25 | 0.0% | 0.3% | ||
| Q1 25 | 0.1% | 0.8% | ||
| Q4 24 | 0.0% | 0.5% | ||
| Q3 24 | 0.2% | 0.9% | ||
| Q2 24 | 0.1% | 0.4% | ||
| Q1 24 | 0.4% | 0.3% |
现金转化率EBHCAT
| Q4 25 | — | — | ||
| Q3 25 | 5.76× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -30.37× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EB
| US | $52.0M | 71% |
| Other | $21.6M | 29% |
HCAT
| Recurring Technology | $51.9M | 69% |
| Professional Services | $22.8M | 31% |
